

Revista Española de Nutrición Humana y Dietética

Spanish Journal of Human Nutrition and Dietetics

INVESTIGACIÓN – versión post-print

Esta es la versión revisada por pares aceptada para publicación. El artículo puede recibir modificaciones de estilo y de formato.

The effect of intuitive eating and conscious eating on glycemic control in individuals with type 2 diabetes: A Cross-sectional Study

El efecto de la alimentación intuitiva y consciente sobre el control glucémico en personas con diabetes tipo 2: un estudio transversal

Meltem Mermer^a, Özlem Özpak Akkuş^a

^a Toros University, Department of Nutrition and Dietetics, Mersin, Türkiye * meltem.mermer@toros.edu.tr

Received: 2023/05/29; accepted: 2023/11/28; published: 2023/12/04

Editor Asignado: Manuel Reig García-Galbis, Universidad Isabel I, Burgos, España.

CITA: Mermer M, Özpak Akkuş Ö. The effect of intuitive eating and conscious eating on

glycemic control in individuals with type 2 diabetes: A Cross-sectional Study. Rev Esp Nutr

Hum Diet. 2023; 27(4). doi: 10.14306/renhyd.27.4.1940 [ahead of print]

La Revista Española de Nutrición Humana y Dietética se esfuerza por mantener a un sistema de publicación continua, de modo que los artículos se publican antes de su formato final (antes de que el número al que pertenecen se haya cerrado y/o publicado). De este modo, intentamos poner los artículos a disposición de los lectores/usuarios lo antes posible.

The Spanish Journal of Human Nutrition and Dietetics strives to maintain a continuous publication system, so that the articles are published before its final format (before the number to which they belong is closed and/or published). In this way, we try to put the articles available to readers/users as soon as possible.

ABSTRACT

Introduction: Eating behavior models such as intuitive eating (IE) and mindful eating (ME) have recently gained importance in a role in providing glycemic control. In this study, we aimed to evaluate the effect of intuitive eating and mindful eating on the dietary treatment of type 2 diabetes mellitus (T2DM) and to investigate their relationship with glycemic control and obesity.

Methods: A total of 153 patients who were diagnosed with T2DM within at least one year and aged between 19 and 64 years were included. Descriptive characteristics of the patients were questioned using face-to-face interviews and anthropometric measurements The Intuitive Eating Scale 2 (IES-2) was used to evaluate intuitive eating behaviors and the Mindful Eating Questionnaire (MEQ) was used to assess mindful eating behaviors.

Results: The total IES-2 score was higher in patients with T2DM who had inadequate glycemic control (p<0.05), and a one-point increase in the IES-2 increased the probability of HbA1c level above 7 % by 25.2 % (p<0.05). There was a moderate negative correlation between the total MEQ score and body weight, BMI, waist circumference, and waist-to-height ratio in the patients with adequate glycemic control (r=-0.526, r=-0.537, r=-0.506, r=-0.510, respectively; p<0.05). There was a weak negative correlation between the total IES-2 score and BMI and between the total MEQ score and waist-to-height ratio, triglyceride, and very low-density lipoprotein cholesterol in the patients with inadequate glycemic control (r=-0.225, r=-0.224, r=-0.114, r=-0.178, respectively; p<0.05).

Conclusions: This study results suggest that intuitive eating adversely affects glycemic control in patients with T2DM and mindful eating is positively associated with body weight control, although it has no direct effect on glycemic control.

Keywords: Diabetes Mellitus, Type 2; Glycated Hemoglobin; Obesity; Intuitive Eating.

RESUMEN

Introducción. Los modelos de comportamiento alimentario como la alimentación intuitiva (IE) y la alimentación consciente (ME) han cobrado importancia recientemente por su papel en el control glucémico. En este estudio, nuestro objetivo fue evaluar el efecto de la alimentación intuitiva y la alimentación consciente en el tratamiento dietético de la diabetes mellitus tipo 2 (DM2) e investigar su relación con el control glucémico y la obesidad.

Metodología. Se incluyeron un total de 153 pacientes diagnosticados de DM2 en al menos un año y con edades comprendidas entre 19 y 64 años. Las características descriptivas de los pacientes fueron obtenidas mediante entrevistas cara a cara y medidas antropométricas. Se utilizó la Escala de alimentación intuitiva 2 (IES-2) para evaluar los comportamientos alimentarios y el Cuestionario de alimentación consciente (MEQ) para evaluar los comportamientos alimentarios conscientes.

Resultados. La puntuación total del IES-2 fue mayor en pacientes con DM2 que tenían un control glucémico inadecuado (p<0.05), y un aumento de un punto en el IES-2 aumentó la probabilidad de que el nivel de HbA1c estuviera por encima del 7 % en un 25.2 % (p<0.05). Hubo una correlación negativa moderada entre la puntuación total del MEQ y el peso corporal, el IMC, la circunferencia de la cintura y la relación cintura-talla en los pacientes con control glucémico adecuado (r=-0.526, r=-0.537, r=-0.506, r=-0.510, respectivamente; p<0.05). Hubo una débil correlación negativa entre la puntuación total del IES-2 y el IMC y entre la puntuación total del MEQ y el índice cintura-talla, triglicéridos y colesterol unido a lipoproteínas de muy baja densidad en los pacientes con control glucémico inadecuado (r=-0.225, r=-0.224, r=-0.114, r=-0.178, respectivamente; p<0.05).

Conclusión. Los resultados de este estudio sugieren que la alimentación intuitiva afecta negativamente el control glucémico en pacientes con DM2 y la alimentación consciente se asocia positivamente con el control del peso corporal, aunque no tiene un efecto directo sobre el control glucémico.

Palabras clave. Diabetes Mellitus Tipo 2; Hemoglobina Glucada; Obesidad; Alimentación Intuitiva.

HIGHLIGHTS

- Since strong food cravings and emotional overeating can impair adherence to dietary recommendations, increasing awareness of patients with T2DM about managing physiological and cognitive processes related to eating may provide additional contribution to the management of T2DM.
- 2. It should not be forgotten that the idea that glycemic control can only be achieved with IE and ME in T2DM patients may lead to poor glycemic control.

INTRODUCTION

About 422 million individuals worldwide suffer from diabetes, and 1.5 million deaths are attributed to diabetes each year¹. A healthy diet is one of the cornerstones of diabetes management. However, deciding what to eat is the most challenging part of the treatment plan for these individuals².

Intuitive eating (IE) is a dietary behavior associated with psychological well-being, characterized by eating in response to physiological hunger and satiety cues rather than external conditions and emotional factors^{3,4}. The Intuitive Eating Scale 2 (IES-2) is a validated tool which measures the degree of adherence to IE behaviors and attitudes⁵. It was originally developed against the failures of classical diets or energy-restricted diets in weight control of individuals and their negative effects on the body. The basic principles are to respond to innate hunger and satiety signals without restriction in the types of food consumed⁶. No restrictions on the types of food an individual can eat are set, unless there are no certain health problems such as diabetes or food allergies, as it is thought that the body can instinctively choose a variety of foods that provide nutritional balance⁶. In some studies, on intuitive eating in individuals with type 2 diabetes, it has been reported that intuitive eating may reduce the risk of inadequate glycemic control, while in some studies it is reported that it will have a positive effect on glycemic control by reducing body weight⁷⁻⁹.

Mindful eating (ME) is the state of being aware of the effect of eating on thoughts, feelings, bodily sensations, and behaviors. Given the various physiological and cognitive processes associated with eating such as memory, attention, and metabolic state, a wide variety of different practices can be defined as ME¹⁰. Most diets follow eating guidelines (*i.e.*, what to eat, how much to eat, and what not to eat) aiming at specific outcomes such as weight loss, good glycemic control, and improved glycated hemoglobin (HbA1c). All diets have the potential for success or failure based on body weight results. Individuals may be aware of that their body weight results depend on their calorie intake and energy expenditure, and they may understand that it is related to their behavior; however, it is difficult to maintain behavior change without seeing results on body weight¹¹. In a study evaluating the eating awareness of individuals with type 2 diabetes, 81 % of individuals with T2DM were found to be slightly overweight and obese, while the incidence of eating disorders in these individuals was changed to be between 7.5 % and 9 %¹². Kes et al. In a study conducted by 2021 using the

MEQ scale, it was found that higher scale scores were associated with decreased BMI values and a lower risk of developing T2DM¹³.

Mindful eating seems to be an effective approach for body weight control and glycemic control in individuals with type 2 diabetes mellitus (T2DM) with promising outcomes. In the present study, we aimed to evaluate the effect of IE and ME on the dietary treatment of T2DM and to investigate their relationship with glycemic control and obesity.

METHODS

This single-center, analytical cross-sectional study was conducted at the Department of Nutrition and Dietetics of a tertiary care center between March 2022 and April 2022. A total of 153 adult patients aged between 19 and 64 years with T2DM who were referred from the Mersin City Training and Research Hospital, Department of Endocrinology and Metabolic Disorders of our center and were diagnosed with T2DM within at least one year were included. Exclusion criteria were as follows: having type 1 diabetes, pregnancy and lactation, malignancies, previous history of bariatric surgery, hypothyroidism, Stage 4-5 chronic renal failure, receiving dialysis, having an eating disorder, psychological disorders, and non-communicable neurological disease.

The study power analysis and sample size calculation were performed using the G*Power 3.1 software (Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany). With an alpha (α)=0.05, power (1- β)=0.95, and medium effect size (d)=0.50, the study power was calculated as 100 % with a sample size of 150. A written informed consent was obtained from each participant. The study was approved by the institutional Toros University Scientific Research and Publication Ethics Committee with Approval No: 113 and Date: 10/12/2021 and Ministry of Health of the Republic of Turkey Approval No: 2 and Date: 09/03/2022. The study was conducted following the principles of the Declaration of Helsinki.

Descriptive characteristics of the patients were questioned using face-to-face interviews including age, sex, marital status, education status, age at the time of diagnosis, treatment duration, and medications used. Anthropometric measurements including body weight, height, body mass index (BMI) waist circumference (WC), and hip circumference (HC) were done. The Intuitive Eating Scale 2 (IES-2) was used to evaluate IE behaviors¹⁴ and the Mindful Eating Questionnaire (MEQ) was used to assess ME behaviors¹⁵. Data including biochemical

parameters such as fasting blood glucose (FBG), HbA1c, fasting insulin, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and very low-density lipoprotein cholesterol (VLDL-C) were retrieved from the patient files.

Glycemic Control. The glycemic control status of individuals with type 2 diabetes participating in the study was evaluated using the HbA1c levels obtained from the individuals' medical records. It was categorized as adequate glycemic control when HbA1c levels ≤ 7 % and insufficient glycemic control when HbA1c >7 % ².

Anthropometric measurements. The body weight, height, WC, and HC were measured by a researcher during face-to-face interviews¹⁶. The BMI values (body weight (kg) / height (m²)) were calculated from body weight and height measurements and classified according to the World Health Organization (WHO) as follows: BMI <18.5 kg/m² underweight, 18.5-24.9 kg/m² normal, 25.0-29.9 kg/m² overweight, and \geq 30.0 kg/m² obese¹⁷. The WC measurements were classified according to the WHO classification as follows: men, <94 cm low risk, 94-101 cm high risk, and \geq 102 cm very high risk; women, <80 cm low risk, 80-87 cm high risk, and \geq 88 cm very high risk¹⁸. The HC and waist-to-hip ratio (WHR) were also measured and classified according to the WHO classification (>0.90 for men and >0.85 for women)¹⁸. The waist-to-height ratio (WHR) was calculated as waist measurement divided by height measurement as described by Ashwell et al.¹⁹ as follows: <0.5 low risk, 0.5-0.6 high risk, and \geq 0.6 very high risk).

IES-2. The IES-2 is a 21-item scale which is used to evaluate IE behaviors. It was developed by Tylka and Kroon Van Diest in 2013⁵ and its validity and reliability studies were carried out by Baş et al.¹⁴ in the Turkish population. It uses a 5-point Likert-type scale from 1=strongly disagree to 5=strongly agree. It consists of four domains of IE: unconditional permission to eat (UPE), eating for physical rather than emotional reasons (EPR), reliance on hunger and satiety cues (RHSC), and body-food choice congruence (B-FCC). The total scores are calculated by dividing the four domains and total score by the total number of items in the relevant area. Higher scores indicate a higher tendency to IE behavior¹⁴.

MEQ. The MEQ is a reliable tool for the assessment of ME behavior of individuals. It was developed by Framson et al.²⁰ and its validity and reliability studies were carried out by Köse et al.¹⁵ in the Turkish population. It consists of 30 items and seven subscales (*i.e.*, disinhibition-

mindless eating, emotional eating, eating control, mindfulness, eating discipline, conscious nutrition, and interference). It uses a 5-point Likert-type scale from 1=None to 5=Always. The total scores are calculated by dividing the seven subscales and total score by the total number of items in the relevant area. Higher scores indicate more mindful attitudes toward eating¹⁵. Statistical Analysis. Statistical analysis was performed using the SPSS version 26.0 software (IBM Corp., Armonk, NY, USA). Descriptive data were presented in mean ± standard deviation (SD), median (min-max) or interquartile range (IQR) or number and frequency, where applicable. The normality of distribution of variables was checked using the Shapiro-Wilk test. The Levene test was used to determine the homogeneity of variance. Independent samples t-test was used to compare normally distributed variables between the two groups, while the Pearson correlation analysis was used to determine the relationship between variables. The Mann-Whitney U test was used to compare non-normally distributed variables and the Spearman correlation analysis was performed to analyze the relationship between variables. The chi-square test was used to compare continuous variables with the Yates and Fisher correction tests. Binary logistic regression analysis was used to identify the factors affecting the HbA1c groups. First, FBG, diabetes management plan, treatment duration, age at the time of diagnosis, and IES-2 total score were included in the regression model. Next, a final logistic regression model (reduced model) was created using the log-likelihood-based backward elimination (backward-LR) method, eliminating non-significant factors. The alpha (α) values of IES-2 and MEQ were calculated as 0.767 and 0.715, respectively. A p value of <0.05 was considered statistically significant.

RESULTS

Sociodemographic characteristics and biochemical test results of the patients according to the HbA1c groups are shown in Table 1. The majority of the patients with inadequate glycemic control were male (n=77, 59.2 %) and were on oral antidiabetic medications alone (n=64, 49.2 %). In these patients, age at the time of diagnosis, treatment duration, and FBG levels were significantly higher than those with adequate glycemic control (p<0.05). In addition, a statistically significant correlation was observed between inadequate glycemic control and WC of women and WHR of both men and women (p<0.05).

57 % 78.3 Test statistic p Age, year (median) 69.5 7.8.3 U=1323 0.381 Sev, n(%)		HbA1c			
(n=2.0) (n=2.3) (n=2.3) Age, year (median) 69.6 78.3 U=1323 0.381 Male 15(65.2) 77(59.2) Fisher X=0.292 0.500 Fernale 8(34.8) 53(40.8) U=1036 0.019 Age at the time of diagnosis, month (median) 57.1 80.3 U=1036 0.019 Treatment Juan, n(%) U U 15(65.2) 71(59.2) Fisher X=8.962 0.009 OAD 198(3.6) 64(49.2) U 0.039 0.039 0.031 U 0.039 0.039 0.031 U 0.039 0.039 0.031 U 0.030 0.039 0.039 0.031 U 0.039 0.039 0.039 0.031 <th></th> <th></th> <th></th> <th>Test statistics</th> <th>p</th>				Test statistics	p
Age, year (median) 69.6 78.3 U=1323 0.381 Sex, n (%) Male 15(65.2) 77(59.2) Fisher X ² =0.292 0.650 Female 8(34.8) 53(40.8) 0.019 0.019 0.019 Treatment duration, month (median) 57.1 80.3 U=1072 0.030 Treatment plan, n (%) 21(15.2) Fisher X ⁴ =8.962 0.009 DAD 2(8.7) 45(34.6) 53(40.8) 0.039 Gassification (kg/m ²), n (%) 1(4.3 2(1.5) Fisher X ² =8.962 0.009 Overweight (52.5-29.9) 3(33.0) 39(30.0) 0 0.020 0.673 Gassification (m, n (%) 1(6.7) 10(8.2) 7(54.6) 0.429 0.673 Classification (m, n (%) 1(25.) Fisher X ² =0.368 0.902 1(8.7) 1(8.7) 1(1.6) 1(1.7) 1(1.8) 1(1.7) 1(1.8) 1(1.7) 1(1.8) 1(1.7) 1(1.8) 1(1.7) 1(1.8) 1(1.7) 1(1.8) 1(1.7) 1(1.8) 1(1.8) 1(1.7) <td></td> <td></td> <td></td> <td></td> <td>•</td>					•
Male 15(6.2) 75.40 Fisher X ² -0.292 0.50 Age at the time of diagnosis, month (median) 57.1 80.5 U=1036 0.191 Treatment duration, month (median) 57.1 80.5 U=1037 0.80 Treatment duration, month (median) 27.1 80.5 U=1072 0.80 Treatment plan, 1%/ U U 10172 0.80 0.90 Insulin QAD 211(5.2) Fisher X ² =8.02 0.90 BMI (kg/m) (meantSD) 33.98.9 31.346.1 I=1.714 0.80 Classification (kg/m ²), n (%) U U 161.3 161.3 1.51.7 K ² =4.08 0.20 Overweight (25.0-29.9) 31.345.1 tellser X ² =4.08 0.21 0.22 0.22 0.22 Obess (23.0) 15(5.2) 7154.6 U U U Wais (caunterence (m) (meale) (meantSD) 212(80.0 55(71.4 U U User kit (54.01 12(80.0 55(71.4 U U U User kit	Age, year (median)			U=1323	0.381
Male 15(6.2) 75.40 Fisher X ² -0.292 0.50 Age at the time of diagnosis, month (median) 57.1 80.5 U=1036 0.191 Treatment duration, month (median) 57.1 80.5 U=1037 0.80 Treatment duration, month (median) 27.1 80.5 U=1072 0.80 Treatment plan, 1%/ U U 10172 0.80 0.90 Insulin QAD 211(5.2) Fisher X ² =8.02 0.90 BMI (kg/m) (meantSD) 33.98.9 31.346.1 I=1.714 0.80 Classification (kg/m ²), n (%) U U 161.3 161.3 1.51.7 K ² =4.08 0.20 Overweight (25.0-29.9) 31.345.1 tellser X ² =4.08 0.21 0.22 0.22 0.22 Obess (23.0) 15(5.2) 7154.6 U U U Wais (caunterence (m) (meale) (meantSD) 212(80.0 55(71.4 U U User kit (54.01 12(80.0 55(71.4 U U U User kit					
Age at the time of diagnosis, month (median)57.187.380.3U=10360.019Treatment plan, n (%) </td <td></td> <td>15(65.2)</td> <td>77(59.2)</td> <td>Fisher X²=0.292</td> <td>0.650</td>		15(65.2)	77(59.2)	Fisher X ² =0.292	0.650
Treatment duration, month (median)58.780.3U=10720.300Treatment plan, n(%)(1) <t< td=""><td>Female</td><td>8(34.8)</td><td>53(40.8)</td><td></td><td></td></t<>	Female	8(34.8)	53(40.8)		
Treatment plan, n (%)21(16.2)1/1 step X = 2.8.7)21(16.2)1/1 step X = 2.8.92)0.009DAD19(82.6)64(49.2)111.8.11.9.1	Age at the time of diagnosis, month (median)	57.1		U=1036	0.019
insulin 2(8,7) 2(116.2) Fisher X ² =8.962 0.009 OAD 19(82.6) 6(49.2) 1	Treatment duration, month (median)	58.7	80.3	U=1072	0.030
OAD 19(82.6) 64(49.2) Insulin + OAD 2(8.7) 45(34.6)	Treatment plan, n (%)				
Insulin + OAD 2(8.7) 45(34.6) BMI (kg/m ²) (meantSD) 33.392.9 31.316.1 t=1.714 0.89 Classification (kg/m ²), n(%) 1(4.3 2(1.5) Fisher X ² =0.084 0.230 Overweight (25.0-29.9) 3(13.0) 39(3.0) -	Insulin	2(8.7)	21(16.2)	Fisher X ² =8.962	0.009
BMI (kg/m²) (meantSD)33.948.931.346.1t=1.7140.089Classification (kg/m²), n (%)1(4.31(1.5)1) (kg/m²) (meantSD)2.30Normal (18.5-24.9)4(17.4)18(13.8)9(30.0)1Overweight (25.0-29.9)3(13.0039(30.0)11Obese (23.0.0)15(5.2)71(54.6)108.312.8t=0.4290.673Classification (cm), n (%)101.3.0112(15.0)Fisher X²=0.3680.902Low risk (594)12(80.0)55(7.4)111Low risk (202)108.312.3108.312.3t=1.5360.163Classification (cm), n (%)12(28.0)55(7.4)11Low risk (680, n) (kg/0)1(12.5)1Fisher X²=0.3680.163Classification (m, n (%)12(28.0)52(8.1)111Low risk (680, R)2(25.0)1(1.9)X²=10.55211Very high risk (280, R)10.12.52(28.0)111 </td <td>OAD</td> <td>19(82.6)</td> <td>64(49.2)</td> <td></td> <td></td>	OAD	19(82.6)	64(49.2)		
Classification (kg/m²), n (%) Kisher X²=4.08 0.230 Underweight (218.5) 1(17.4) 18(13.8) 0.230 Overweight (25.0-29.9) 3(13.0) 39(3.0.0) - - Obese (230.0) 15(65.2) 71(54.6) - - - Waist circumference (m) (male) (mean±SD) 15(65.2) 71(54.6) - <td>Insulin + OAD</td> <td>2(8.7)</td> <td>45(34.6)</td> <td></td> <td></td>	Insulin + OAD	2(8.7)	45(34.6)		
Underweight (-13.5) Fisher X ³ =4.084 0.230 Normal (13.5-24.9) 4(17.4) 18(13.8)	BMI (kg/m ²) (mean±SD)	33.9±8.9	31.3±6.1	t=1.714	0.089
Normal (12.5-24.9) 4(17.4) 18(13.8) Overweight (25.0-29.9) 3(13.0) 39(30.0) Obese (230.0) 15(65.2) 71(54.6) Waist circumference (cm) (male) (mean±SD) 108.3±12.9 106.8±13.5 t=0.429 0.673 Classification (cm), n (%) 10(13.0) 12(15.6) Fisher X²=0.368 0.902 High risk (94-101) 1(6.7) 10(13.0) 12(80.0) 55(71.4) 1003 Very high risk (210.2) 12(80.0) 55(71.4) 1003.312.23 t=0.1536 0.016 Vaist circumference (cm) (female) (mean±SD) 88.312.3 108.3±12.3 t=0.1536 0.163 Classification (cm), n (%) 1(12.5) - Fisher 0.006 Urey high risk (80.87) 2(25.0) 1(12.5) - Fisher 0.016 Classification, n (%) 11(73.3) 20(26.0) 1(2.5) - 1.013.0 1.013.0 1.013.0 1.013.0 1.013.0 1.013.0 1.013.0 1.013.0 1.013.0 1.013.0 1.015.0 1.015.0 1.015.0 1.015.0	Classification (kg/m²), n (%)				
Overweight (25.0-29.9) 3(13.0) 3(13.0) 3(13.0) Obese (≥30.0) 15(6.2) 71(5+.6) Waist circumference (cm) (male) (meantSD) 108.3±1.2.9 106.8±1.3.5 1-0.429 0.673 Classification (cm), n (%) 1 10(13.0) Fisher X ² -0.368 0.902 Low risk (<94)	Underweight (<18.5)	1(4.3	2(1.5)	Fisher X ² =4.084	0.230
Obese (>30.0) 15(65.2) 71(54.6) Vertex Waist circumference (cm) (male) (mean±SD) 108.312.9 108.312.9 10.621.35 t=0.429 0.673 Classification (cm), n (%) 2[13.3) 12[15.6) Fisher X ² =0.368 0.902 High risk (94-101) 10(5.7) 10(13.0) Verv high risk (2102) 12(80.0) 55(71.4) Verv high risk (2102) 12(80.0) 55(71.4) Verv high risk (2102) 108.3±12.3 108.3±12.3 108.3±12.3 108.3±12.3 108.3±12.3 108.3±12.3 108.3±12.3 10.05 Classification (cm), n (%) 112.5) - Fisher 0.006 User risk (0.807) 2[25.0) 1(1.9) X ² =10.572 Vert high risk (280.87) 0.902.0 1.90.9 Vertex Classification (n%) 11(2.5) 52(92.1) Vertex Verte	Normal (18.5-24.9)	4(17.4)	18(13.8)		
Waist circumference (cm) (male) (mean±SD)108.3±12.9108.3±12.9106.8±13.5t=0.4290.673Classification (cm), n (%)2(13.012(15.6)Fisher X²=0.3680.90High risk (94-101)10(17.0)10(13.0)12(80.0)55(71.4)1Very high risk (202)12(80.0)55(71.4)11.6730.163Classification (cm), n (%)112.5)10.83±12.3108.3±12.410.670.163Classification (cm), n (%)11.5.552(8.1)11.91.	Overweight (25.0-29.9)	3(13.0)	39(30.0)		
Classification (cm), n (%) 2(13.3) 12(15.6) Fisher X ² =0.36 0.902 High risk (94.101) 16(7) 10(13.0)	Obese (≥30.0)	15(65.2)	71(54.6)		
Low risk (<94) 2(13.3) 12(15.6) Fisher X ² =0.368 0.902 High risk (94-101) 10(13.0) 10(13.0) 10(13.0) 10(13.0) Very high risk (2102) 12(80.0) 55(71.4) 12(80.0) 55(71.4) Classification (m), n (%) 11(2.5) - Fisher 0.006 Low risk (<80)	Waist circumference (cm) (male) (mean±SD)	108.3±12.9	106.8±13.5	t=0.429	0.673
High risk (94-101) 1(6.7) 10(13.0) Very high risk (≤102) 12(80.0) 55(71.4) Waist circumference (cm) (female) (mean±SD) 98.3±12.3 108.3±12.3 t=1.536 0.163 Classification (cm), n (%) 1(12.5) - Fisher 0.006 Low risk (<80)	Classification (cm), n (%)				
Very high risk (≥102) 12(80.0) 55(71.4) Wait circumference (cm) (female) (mean±SD) 98.3±12.3 108.3±12.3 t=1.536 0.163 Classification (cm), n (%) Fisher 0.006 Low risk (c80) 1(12.5) - Fisher 0.006 High risk (80-87) 2(25.0) 1(1.9) X²=10.552 Very high risk (888) 5(62.5) 52(98.1) Classification, n (%) 0.8±0.1 0.9±0.1 t=3.784 <0.01	Low risk (<94)	2(13.3)	12(15.6)	Fisher X ² =0.368	0.902
Waist Circumference (cm) (female) (mean±SD) 98.3±12.3 108.3±12.3 t=1.536 0.163 Classification (cm), n (%) 1(12.5) - Fisher 0.06 Low risk (<80)	High risk (94-101)	1(6.7)	10(13.0)		
Classification (cm), n (%) Fisher 0.006 Low risk (<80)	Very high risk (≥102)	12(80.0)	55(71.4)		
Low risk (<80) 1(12.5) - Fisher 0.006 High risk (80-87) 2(25.0) 1(1.9) X ² =10.552 · Very high risk (288) 5(62.5) 52(98.1) · · WHR (male) (meantSD) 0.8±0.1 0.9±0.1 t=3.784 <0.001	Waist circumference (cm) (female) (mean±SD)	98.3±12.3	108.3±12.3	t=-1.536	0.163
High risk (80-87)2(25.0)1(1.9)X²=10.552Very high risk (≥88)5(62.5)52(98.1)	Classification (cm), n (%)				
Very high risk (≥88) 5(62.5) 52(98.1) WHR (male) (meantSD) 0.8±0.1 0.9±0.1 t=3.784 <0.001	Low risk (<80)	1(12.5)	-	Fisher	0.006
WHR (male) (mean±SD) 0.8±0.1 0.9±0.1 t=-3.784 <0.011 Classification, n (%) 11(73.3) 20(26.0) X ² =10.573 <0.011	High risk (80-87)	2(25.0)	1(1.9)	X ² =10.552	
Classification, n (%) 11(73.3) 20(26.0) X ² =10.573 <0.001	Very high risk (≥88)	5(62.5)	52(98.1)		
Low risk (0.90) 11(73.3) 20(26.0) X ² =10.573 <0.01 High risk (20.90) 4(26.7) 57(74.0) 0.146 Classification, n (%) 0.9±0.0 1.0±0.0 t=-1.607 0.146 Classification, n (%) 2(25.0) - 0.015 High risk (20.85) 2(25.0) - 0.015 High risk (20.85) 0.7±0.1 0.7±0.0 t=-0.432 0.626 Classification, n (%) 0.7±0.1 0.7±0.0 t=-0.432 0.626 Classification, n (%) 0.7±0.1 0.7±0.0 t=-0.432 0.626 Classification, n (%) 16(69.6) 96(85.7) Fisher X ² =3.506 0.181 Low risk (<0.5)		0.8±0.1	0.9±0.1	t=-3.784	<0.001
High risk (≥0.90)4(26.7)57(74.0)WHR (female) (mean±SD)0.9±0.01.0±0.0t=1.6070.146Classification, n (%)2(25.0)-0.015Low risk (0.85)2(25.0)53(100)-0.015High risk (≥0.85)6(75.0)53(100)t=-0.4320.626Classification, n (%)0.7±0.10.7±0.0t=-0.4320.626Classification, n (%)0.7±0.10.7±0.0t=-0.4320.626Classification, n (%)16(69.6)96(85.7)Fisher X²=3.5060.181High risk (<0.5)	Classification, n (%)				
WHR (female) (mean±SD) 0.9±0.0 1.0±0.0 t=1.607 0.146 Classification, n (%) 2(25.0) - 0.015 Low risk (0.85) 6(75.0) 53(100) t=0.432 0.626 WHR (mean±SD) 0.7±0.1 0.7±0.0 t=0.432 0.626 Classification, n (%) t=0.05 t=0.432 0.626 Low risk (<0.5) 16(69.6) 96(85.7) Fisher X ² =3.506 0.181 High risk (0.5-0.6) 2(8.7) 2(1.5) t=0.123 0.181 Very high risk (≥0.6) 87.3 U=157 <0.001 FBG (mg/dL) 18.9 87.3 U=1213	Low risk (0.90)		20(26.0)	X ² =10.573	<0.001
Classification, n (%) 2(25.0) - 0.015 Low risk (0.85) 6(75.0) 53(100) - 0.015 WHtR (mean±SD) 0.7±0.1 0.7±0.0 t=0.432 0.626 Classification, n (%) 0.7±0.1 0.7±0.0 t=0.432 0.626 Classification, n (%) 0.7±0.1 0.7±0.0 t=0.432 0.626 Low risk (<0.5)		4(26.7)	57(74.0)		
Low risk (0.85)2(25.0)-0.015High risk (≥0.85)6(75.0)53(100)1WHR (mean±SD)0.7±0.10.7±0.0t=-0.4320.626Classification, n (%)16(69.6)96(85.7)Fisher X²=3.5060.181Low risk (<0.5)		0.9±0.0	1.0±0.0	t=-1.607	0.146
High risk (≥0.85)6(75.0)53(100)WHtR (mean±SD)0.7±0.0t=0.4320.626Classification, n (%)t=0.4320.626Low risk (<0.5)16(69.6)96(85.7)Fisher X²=3.5060.181High risk (0-5-0.6)2(21.7)32(24.6)t=0.151.100Very high risk (≥0.6)2(8.7)2(1.5)t=0.157<0.001Biochemical test results (median)18.987.3U=157<0.001TG (mg/dL)64.779.2U=12130.150TC (mg/dL)79.269.4U=11680.292HDL-C (mg/dL)92.474.3U=11400.070VLDL-C (mg/dL)67.678.7U=12780.269					
WHR (mean±SD)0.7±0.0t=-0.4320.626Classification, n (%) </td <td></td> <td></td> <td>-</td> <td></td> <td>0.015</td>			-		0.015
Classification, n (%)16(69.6)96(85.7)Fisher X²=3.5060.181Low risk (<0.5)					
Low risk (<0.5)16(69.6)96(85.7)Fisher X²=3.5060.181High risk (0-5-0.6)5(21.7)32(24.6)2(8.7)2(1.5)Very high risk (≥0.6)2(8.7)2(1.5)11Biochemical test results (median)18.987.3U=157<0.001		0.7±0.1	0.7±0.0	t=-0.432	0.626
High risk (0-5-0.6)5(21.7)32(24.6)Very high risk (≥0.6)2(8.7)2(1.5)Biochemical test results (median)18.987.3U=157FBG (mg/dL)64.779.2U=1213TG (mg/dL)64.779.2U=1451TC (mg/dL)78.976.7U=1451LDL-C (mg/dL)79.269.4U=1168HDL-C (mg/dL)92.474.3U=1140VLDL-C (mg/dL)67.678.7U=1278OLD0.2690.269					
Very high risk (≥0.6)2(8.7)2(1.5)Biochemical test results (median)18.987.3U=157FBG (mg/dL)18.987.3U=12130.150TG (mg/dL)64.779.2U=12130.150TC (mg/dL)78.976.7U=14510.824LDL-C (mg/dL)79.269.4U=11680.292HDL-C (mg/dL)92.474.3U=11400.070VLDL-C (mg/dL)67.678.7U=12780.269				Fisher X ² =3.506	0.181
Biochemical test results (median)FBG (mg/dL)18.987.3U=157<0.001					
FBG (mg/dL)18.987.3U=157<0.001TG (mg/dL)64.779.2U=12130.150TC (mg/dL)78.976.7U=14510.824LDL-C (mg/dL)79.269.4U=11680.292HDL-C (mg/dL)92.474.3U=11400.070VLDL-C (mg/dL)67.678.7U=12780.269		2(8.7)	2(1.5)		
TG (mg/dL)64.779.2U=12130.150TC (mg/dL)78.976.7U=14510.824LDL-C (mg/dL)79.269.4U=11680.292HDL-C (mg/dL)92.474.3U=11400.070VLDL-C (mg/dL)67.678.7U=12780.269					
TC (mg/dL)78.976.7U=14510.824LDL-C (mg/dL)79.269.4U=11680.292HDL-C (mg/dL)92.474.3U=11400.070VLDL-C (mg/dL)67.678.7U=12780.269					
LDL-C (mg/dL)79.269.4U=11680.292HDL-C (mg/dL)92.474.3U=11400.070VLDL-C (mg/dL)67.678.7U=12780.269					
HDL-C (mg/dL)92.474.3U=11400.070VLDL-C (mg/dL)67.678.7U=12780.269					
VLDL-C (mg/dL) 67.6 78.7 U=1278 0.269					
					0.269

Table 1. Sociodemographic characteristics and biochemical test results of the patients according to the HbA1c levels

*t test; Mann-Whitney U; Fisher chi-square; BMI: Body Mass Index; DM: Diabetes Mellitus; FBG: Fasting Blood Glucose; HbA1c: Glycohemoglobin; HDL-C: High-Density Lipoprotein Cholesterol; LDL-C: Low-Density Lipoprotein Cholesterol; OAD: oral antidiabetic; TC: total cholesterol; TG: triglyceride; VLDL-C: Very Low-Density Lipoprotein Cholesterol; WHR: waist-to-hip ratio; WHtR: waist-to-height ratio. The IES-2 and total MEQ scores and subscale scores according to the HbA1c groups revealed that only IES-2 total scores were significantly higher in the patients with inadequate glycemic control (p<0.05) (Table 2).

	HbA1c			
	≤7 %	>7 %	Test statistics	р
IES-2				
UPE	3.3±1.1	3.7±1.0	t=-1.660	0.107
EPR	3.4±1.0	3.7±1.1	t=-1.884	0.070
RHSC	3.4±1.5	3.4±1.3	t=-1.251	0.220
B-FCC	3.2±0.7	3.5±0.6	t=-0.054	0.957
Total score	2.8±0.9	3.2±0.9	t=-2.329	0.027
MEQ				
Disinhibition	3.3±1.0	3.6±0.9	t=-1.235	0.227
Emotional eating	4.0±1.1	4.2±0.8	t=-1.094	0.276
Eating control	3.9±1.0	3.7±1.0	t=0.763	0.451
Mindfulness	3.5±0.5	3.5±0.5	t=-0.185	0.855
Eating discipline	3.1±0.9	2.8±0.9	t=1.731	0.094
Conscious nutrition	2.9±0.6	3.0±0.6	t=-1.059	0.297
Interference	4.0±0.9	3.9±0.9	t=0.237	0.814
Total score	3.5±0.6	3.5±0.4	t=-0.324	0.746

Table 2. Intuitive eating and mindful eating of patients according to HbA1c levels

*t test; HbA1c: Glycohemoglobin; IES-2: Intuitive Eating Scale 2; MEQ: Mindful Eating Questionnaire; UPE: unconditional permission to eat; EPR: eating for physical rather than emotional reasons; RHSC: reliance on hunger and satiety cues; B-FCC: body-food choice congruence.

The correlations between anthropometric and biochemical test results of the patients according to the HbA1c groups and IE and ME behavior are shown in Table 3. There was a moderate negative correlation between the total MEQ score and body weight, BMI, WC, and WHtR in the patients with adequate glycemic control (r=-0.526, r=-0.537, r=-0.506, r=-0.510, respectively; p<0.05). There was a weak negative correlation between the total IES-2 score and BMI and between the total MEQ score and WHtR, TG, and VLDL-C in the patients with inadequate glycemic control (r=-0.178, respectively; p<0.05).

The coefficients of independent variables included in the full and reduced logistic regression analysis are shown in Table 4. In the full model, only FBG was a significant independent variable (p<0.05). In the reduced model, treatment duration was excluded and FBG, age at the time of diagnosis, and IES-2 scores were found to have a statistically significant effect on HbA1c (p<0.05). In the reduced model using odds ratios, a one-unit increase in FBG, a oneyear increase in the age at the time of diagnosis, and a one-point increase in the IES-2 score increased the probability of HbA1c levels above 7 % by 9.9 %, 13.2 %, and 25.2 %, respectively.

			ochenned	measurer	nento			
	HbA1c							
	≤7 %				>7 %			
	IES-2		MEQ		IES-2		MEQ	
	r	р	r	Р	r	р	r	р
Body weight (kg)	-0.328	0.127*	-0.526	0.010*	0.117	0.184*	-0.120	0.173*
BMI (kg/m²)	-0.391	0.065*	-0.537	0.008*	-0.225	0.010*	-0.099	0.260*
WC (cm)	-0.257	0.236*	-0.506	0.014*	-0.163	0.064*	-0.170	0.053*
WHR	0.275	0.203*	0.055	0.805*	0.156	0.076**	-0.061	0.493**
WHtR	-0.300	0.164*	-0.510	0.013*	-0.130	0.141*	-0.224	0.010*
FBG (mg/dL)	-0.149	0.498*	0.222	0.309*	0.021	0.810**	-0.058	0.513**
TG (mg/dL)	-0.266	0.219*	0.116	0.599*	0.089	0.313**	-0.114	0.027**
TC (mg/dL)	-0.075	0.735*	0.112	0.610*	0.005	0.953**	-0.091	0.305**
LDL-C (mg/dL)	0.113	0.608*	0.112	0.332*	-0.086	0.357**	-0.006	0.951**
HDL-C (mg/dL)	-0.316	0.634**	0.360	0.092**	0.042	0.637**	0.085	0.335**
VLDL-C (mg/dL)	-0.265	0.221*	0.117	0.594*	0.061	0.493**	-0.178	0.043**

Table 3. Correlation of intuitive eating and mindful eating with anthropometric and biochemical measurements

*Pearson; ** Spearman; BMI: Body Mass Index; FBG: Fasting Blood Glucose; HbA1c: Glycohemoglobin; HDL-C: High-Density Lipoprotein Cholesterol; IES-2: Intuitive Eating Scale; LDL-C: Low-Density Lipoprotein Cholesterol; VLDL-C: Very Low-Density Lipoprotein Cholesterol; MEQ: Mindful Eating Questionnaire; TG: triglyceride; TC: total cholesterol; WC: waist circumference; WHR: waist-to-hip ratio; WHtR: waist-to-height ratio.

Model	Coefficient		95 % CI		
		OR	Lower	Upper	-р
Full model	FBG	1.105	1.048	1.164	<0.001
	Treatment plan (Ref=Insulin+OAD)				
	Treatment plan (OAD)	6.401	0.211	193.997	0.286
	Treatment plan (Insulin)	0.420	0.059	2.998	0.387
	Treatment duration	0.827	0.512	1.336	0.438
	Age at the time of diagnosis	1.350	0.840	2.170	0.215
	IES-2 total	3.052	0.996	9.353	0.051
	Constant	0.000			<0.001
Reduced	FBG	1.099	1.047	1.153	<0.001
model	Treatment plan (Ref=Insulin+OAD)				
	Treatment plan (OAD)	5.518	0.202	150.376	0.311
	Treatment plan (Insulin)	0.351	0.048	2.564	0.302
	Age at the time of diagnosis	1.132	1.005	1.275	0.041
	IES-2 total	3.252	1.063	9.946	0.039
	Constant	0.000			<0.001

Table 4. Coefficient statistics for regression models

OR: odds ratio, CI: confidence interval; FBG: fasting blood glucose; OAD: oral antidiabetic; IES-2: Intuitive Eating Scale 2.

DISCUSSION

In the present study, we investigated the effect of IE and ME on the dietary treatment of T2DM and examined their relationship with glycemic control and obesity. Our study results showed that IE adversely affected glycemic control in patients with T2DM, while ME did not have a direct effect on HbA1c, although it was positively correlated with body weight control. The American Diabetes Association (ADA) recommends an HbA1c of \leq 7 % for the treatment of adults with T2DM². To achieve this goal, it is recommended to support body weight loss and reduce energy intake in T2DM adults who are mildly overweight or have obesity. In addition, the ADA recommends that a variety of eating patterns (*i.e.*, combinations of different foods or food groups) can be applied for the management of T2DM, considering individual preferences such as tradition, culture, religion, health beliefs and goals, economics and metabolic goals while choosing an eating pattern over the other².

Eating behavior models such as IE and ME have recently gained importance in body weight control and have been proposed to play a role in providing glycemic control²¹; therefore, these models have begun to be studied in patients with diabetes^{7,22,23}. Previous studies have shown that the IES-2 total score and B-FCC subscale score are effective in providing better glycemic control in patients with T2DM⁷. A study including children and adolescents with type 1 diabetes reported that higher IES-2 total score and EPR subscale scores were associated with lower HbA1c²³. In another study, the IES-2 total score and EPR subscale score positively affected HbA1c and FBG in gestational diabetes²². Unlike the aforementioned studies, we obtained controversial results in our study. The IES-2 total scores were significantly higher in the patients with inadequate glycemic control. In addition, a one-point increase in the IES-2 increased the probability of HbA1c level above 7 % by 25.2 %. Consistent with our findings, a study of African-American women with T2DM showed poor agreement of self-reported dietary practices with IE concepts²⁴. Therefore, the difference in portion perception in some T2DM patients results in confusion in portion control. In the aforementioned study, patients with T2DM believed that larger-sized individuals needed much more energy and, therefore, they did not respect to the advice to eat less after being diagnosed with diabetes. It is thought that, in T2DM, the changes in brain responses to food stimuli are different from healthy individuals and the IE method may be misleading due to their strong cravings for food stimuli and changes in brain responses to emotional overeating²⁵. We think that these results, which

contradict the positive effect of the intuitive eating model on T2DM according to the literature, may be due to the fact that the number of individuals with poor glycemic control in the study was higher than those with good glycemic control.

Overeating can be overcome by improving attention, improving awareness of current events, and focusing on the food itself²⁶. Mindful eating can facilitate body weight management by promoting healthier eating²⁷. It is helpful for individuals to develop awareness of both internal and external stimuli for eating, stop eating automatically, and eat in response to natural physiological cues of hunger and satiety. It can also improve irregular eating and dietary habits²⁸. However, in a systematic review, a limited number of evidence showed that IE and ME interventions affected energy intake or diet quality²⁹. Furthermore, some studies on ME and T2DM have demonstrated that ME reduces HbA1c levels^{30,31}, while some others have not observed significant changes in HbA1c levels^{32,33}. Our study results do not support the presence of an association between ME and HbA1c. We think that this may be due to the difference in the amount of food consumption of individuals with type 2 diabetes who participated in the study.

It has been well established that there is a strong relationship between T2DM development and abdominal obesity³⁴. Obesity markers such as WHR and WHtR are better predictors than BMI for poor glycemic control³⁵. In a study, Miller et al.³⁰ reported that ME and diabetes selfmanagement education improved body weight loss and glycemic control. In addition, changes in body composition that develop with weight loss provide improvements in glycemic control markers and metabolic improvements. Therefore, blood glucose regulation control with individual nutrition programs and body composition monitoring in consultation with a dietician is recommended for individuals with diabetes.³⁶⁻³⁸ In our study, the number of male and female patients with high WHR was significantly higher among those with inadequate glycemic control. On the other hand, there was a negative and significant correlation between ME and body weight, BMI, WC, and WHtR in patients with adequate glycemic control. These findings suggest that ME has positive effects on body weight control with improved glucose control. However, short-term appetite regulation with insulin, not blood glucose level in healthy individuals, has been shown to be impaired in overweight and obese individuals³⁹. Therefore, it may be risky to conclude that only ME can be used reliably to reduce energy intake for patients with diabetes.

Dietary habits and diet therapy are one of the mainstays to achieve blood glucose targets in diabetes². While IE is the main determinant for eating habits in response to physiological hunger and satiety cues, ME consists of making conscious food choices, being aware of physical and psychological hunger and satiety cues, and eating health^{3,4,10}. In the present study, we investigated the effects of IE and ME on the glycemic control of patients with T2DM. The main limitation to this study is the relatively small sample size with good glycemic control, as the vast majority of the patients who were admitted to the Department of Nutrition and Dietetics had impaired glycemic control. Another limitation is the lack of food consumption records of individuals with type 2 diabetes who participated in the study.

CONCLUSIONS

In conclusion, T2DM is a preventable disease, and its associated complications can be prevented with healthy and regular dietary habits. Several aspects should be considered while evaluating HbA1c levels in these patients. Of note, living with diabetes for long years may result in fatigue or non-adherence to diet therapy. A strong craving for food, particularly emotional overeating, may impair adherence to dietary recommendations. Therefore, improving the awareness of patients with T2DM to manage the physiological and cognitive processes related to eating in diet therapy may provide additional contribution to the T2DM management. However, it should be kept in mind that the idea that glycemic control of T2DM patients can be achieved with only IE and ME may yield poor glycemic control. Although dietary habits are the leading factors affecting glucose control in T2DM, age at the time of diagnosis is also a prognostic factor. Further large-scale, prospective studies including age matched T2DM patients with good glycemic control are needed to elucidate the direct effects of IE and ME on T2DM.

ACKNOWLEDGMENTS

We would like to thank all the individuals for their cooperation who participated in our study. **COMPETING INTERESTS**

The authors declare that they have no potential conflict of interest regarding the investigation, authorship, and/or publication of this article.

AUTHORS' CONTRIBUTIONS

MM, ÖÖA: Idea, Study creation, design. MM: Data collection. ÖÖA: Analysis. MM, ÖÖA: Literature review, writing. All authors read and approved the final manuscript.

FUNDING

This study received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

REFERENCES

1. World Health Organization. Diabetes. [Internet]. 2023. [accessed 13 February 2023]. Disponible en: <u>https://www.who.int/health-topics/diabetes#tab=tab_1</u>

2. Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care. 2013;36(11):3821-42, <u>https://doi.org/10.2337/dc13-2854</u>.

3. Tribole E, Resch E. Intuitive eating: A revolutionary program that works . New York: St. 2012, Martin's Press.

4. Tylka TL. Development and psychometric evaluation of a measure of intuitive eating. J Couns Psychol. 2006;53(2):226–240, <u>https://doi.org/10.1037/0022-0167.53.2.226</u>.

5. Tylka TL, Kroon Van Diest AM. The Intuitive Eating Scale–2: Item refinement and psychometric evaluation with college women and men. J Couns Psychol. 2013;60(1):137, <u>https://doi.org/10.1037/a0030893</u>.

6. Van Dyke N, Drinkwater EJ. Review article relationships between intuitive eating and health indicators: literature review. Public Health Nutrition. 2014;17(8);1757-1766, <u>https://doi.org/10.1017/S1368980013002139</u>.

7. Soares FLP, Ramos MH, Gramelisch M, de Paula Pego Silva R, da Silva Batista J, Cattafesta M, Salaroli LB. Intuitive eating is associated with glycemic control in type 2 diabetes. Eat Weight Disorders. 2021;26(2):599-608, <u>https://doi:10.1007/s40519-020-00894-8</u>.

8. Tylka TL, Calogero RM, Daníelsdóttir S. Intuitive eating is connected to self-reported weight stability in community women and men. Eating Disorders. 2019:1-9, https://doi:10.1080/10640266.2019.1580126.

9. Koçak Ö, Yıldırım Y, Şarer Yürekli B. Tip 2 diabetes mellitus hastalarında sezgisel yemenin yeme tutumu ve glisemik kontrol ile ilişkisi. Ege Tıp Dergisi. 2022;61(3):360-370, <u>https://doi.org/10.19161/etd.1167421</u>.

10. Higgs S, Spetter MS, Thomas JM, Rotshtein P, Lee M, Hallschmid M, et al. Interactions between metabolic, reward and cognitive processes in appetite control: Implications for novel weight management therapies. Journal of Psychopharmacology. 2017;31(11):1460-1474, https://doi.org/10.1177/0269881117736917.

11. Nelson JB. Mindful eating: the art of presence while you eat. Diabetes Spectrum. 2017; 30(3): 171-174, <u>https://doi.org/10.2337/ds17-0015</u>.

12. Herpertz S, Albus C, Lichtblau K, Köhle K, Mann K, Senf, W. Relationship of weight and eating disorders in type 2 diabetic patients: a multicenter study. International Journal of

Eating Disorders. 2000; 28(1): 68-77, <u>https://doi.org/10.1002/(SICI)1098-108X(200007)28:1<68::AID-EAT8>3.0.CO;2-R</u>

13. Kes D, Can Cicek S. Mindful eating, obesity, and risk of type 2 diabetes in university students: A cross-sectional study. Nursing Forum. 2021; 56(3): 483-489, https://doi.org/10.1111/nuf.12561.

14. Bas M, Karaca KE, Saglam D, Arıtıcı G, Cengiz E, Köksal S, et al. Turkish version of the Intuitive Eating Scale-2: Validity and reliability among university students. Appetite. 2017; 114: 391-397, <u>https://doi.org/10.1016/j.appet.2017.04.017</u>.

15. Köse G, Tayfur M, Birincioğlu İ, Dönmez A. Adaptation study of the mindful eating questionnare (MEQ) into Turkish. JCBPR. 2018;5(3):125-125, http://dx.doi.org/10.5455/JCBPR.250644.

16. Lohman T, Roche AF, Martorell R. Anthropometric standardization reference manual. 1st ed. Human kinetics; 1988.

17. Consultation, WHO. Obesity: preventing and managing the global epidemic. World Health Organization technical report series. 2000;894:1-253.

18. World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008. [Internet] 2008. [accessed 13 February 2022]. Disponible en: <u>https://www.who.int/publications/i/item/9789241501491</u>.

19. Ashwell M, Gibson S. Waist-to-height ratio as an indicator of 'early health risk': simpler and more predictive than using a 'matrix'based on BMI and waist circumference. BMJ Open. 2016;6(3):e010159, <u>http://dx.doi.org/10.1136/bmjopen-2015-010159</u>.

20. Framson C, Kristal AR, Schenk JM, Littman AJ, Zeliadt S, Benitez D. Development and validation of the mindful eating questionnaire. J Am Diet Assoc. 2009;109(8):1439-1444, <u>https://doi.org/10.1016/j.jada.2009.05.006</u>.

21. Mathieu J. What should you know about mindful and intuitive eating? J Am Diet Assoc. 2009; 109(12): 1982-7, <u>https://doi.org/10.1016/j.jada.2009.10.023</u>.

22. Quansah DY, Gross J, Gilbert L, Helbling C, Horsch A, Puder JJ. Intuitive eating is associated with weight and glucose control during pregnancy and in the early postpartum period in women with gestational diabetes mellitus (GDM): A clinical cohort study. Eat Behav. 2019; 34: 101304, <u>https://doi.org/10.1016/j.eatbeh.2019.101304</u>.

23. Wheeler BJ, Lawrence J, Chae M, Paterson H, Gray AR, Healey D, Reith DM, Taylor BJ. Intuitive eating is associated with glycaemic control in adolescents with type I diabetes mellitus. Appetite. 2016; 96: 160-165, <u>https://doi.org/10.1016/j.appet.2015.09.016</u>.

24. Willig AL, Richardson BS, Agne A, Cherrington A. Intuitive eating practices among African-American women living with type 2 diabetes: a qualitative study. J Acad Nutr Diet. 2014; 114(6): 889-896, <u>https://doi.org/10.1016/j.jand.2014.02.004</u>.

25. Chechlacz M, Rotshtein P, Klamer S, Porubská K, Higgs S, Booth D, Fritsche A, Preissl H, Abele H, Birbaumer N, Nouwen A. Diabetes dietary management alters responses to food pictures in brain regions associated with motivation and emotion: a functional magnetic resonance imaging study. Diabetologia. 2009;52(3):524-33, <u>https://doi.org/10.1007/s00125-008-1253-z</u>.

26. Brown KW, Ryan RM, Creswell JD. Mindfulness: Theoretical foundations and evidence for its salutary effects. Psychological inquiry. 2007;18(4):211-237, https://doi.org/10.1080/10478400701598298.

27. Dalen J, Smith BW, Shelley BM, Sloan AL, Leahigh L, Begay D. Pilot study: Mindful Eating and Living (MEAL): weight, eating behavior, and psychological outcomes associated with a

mindfulness-based intervention for people with obesity. Complement Ther Med. 2010;18(6):260-4, <u>https://doi.org/10.1016/j.ctim.2010.09.008</u>.

28. Miller CK. Mindful Eating With Diabetes. Diabetes Spectr. 2017;30(2):89-94, https://doi.org/10.2337/ds16-0039.

29. Grider HS, Douglas SM, Raynor HA. The Influence of Mindful Eating and/or Intuitive Eating Approaches on Dietary Intake: A Systematic Review. J Acad Nutr Diet. 2021;121(4):709-727, https://doi.org/10.1016/j.jand.2020.10.019.

30. Miller CK, Kristeller JL, Headings A, Nagaraja H, Miser WF. Comparative effectiveness of a mindful eating intervention to a diabetes self-management intervention among adults with type 2 diabetes: a pilot study. J Acad Nutr Diet. 2012;112(11):1835-42, https://doi.org/10.1016/j.jand.2012.07.036.

31. Rosenzweig S, Reibel DK, Greeson JM, Edman JS, Jasser SA, McMearty KD, Goldstein BJ. Mindfulness-based stress reduction is associated with improved glycemic control in type 2 diabetes mellitus: a pilot study. Altern Ther Health Med. 2007;13(5):36-8.

32. Tovote KA, Fleer J, Snippe E, Peeters AC, Emmelkamp PM, Sanderman R, Links TP, Schroevers MJ. Individual mindfulness-based cognitive therapy and cognitive behavior therapy for treating depressive symptoms in patients with diabetes: results of a randomized controlled trial. Diabetes Care. 2014; 37(9): 2427-34, <u>https://doi.org/10.2337/dc13-2918</u>.

33. van Son J, Nyklícek I, Pop VJ, Blonk MC, Erdtsieck RJ, Spooren PF, Toorians AW, Pouwer F. The effects of a mindfulness-based intervention on emotional distress, quality of life, and HbA(1c) in outpatients with diabetes (DiaMind): a randomized controlled trial. Diabetes Care. 2013;36(4):823-30, <u>https://doi.org/10.2337/dc12-1477</u>.

34. Freemantle N, Holmes J, Hockey A, Kumar S. How strong is the association between abdominal obesity and the incidence of type 2 diabetes? Int J Clin Pract. 2008;62(9):1391-6, <u>https://doi.org/10.1111/j.1742-1241.2008.01805.x</u>.

35. Oumer A, Ale A, Tariku Z, Hamza A, Abera L, Seifu A. Waist-to-hip circumference and waistto-height ratio could strongly predict glycemic control than body mass index among adult patients with diabetes in Ethiopia: ROC analysis. PLoS One. 2022;17(11):e0273786, https://doi.org/10.1371/journal.pone.0273786.

36. Caixàs A, Villaró M, Arraiza C, Montalvá JC, Lecube A, Fernández-García JM, et al. SEEDO-SEMERGEN consensus document on continuous care of obesity between Primary Care and Specialist Hospital Units 2019. Med Clin (Barc). 2020; 155(6): 267.e1-267.e11, https://doi.org/10.1016/j.medcle.2019.10.010.

37. Hassapidou M, Vlassopoulos A, Kalliostra M, Govers E, Mulrooney H, Ells L, et al. European Association for the Study of Obesity Position Statement on Medical Nutrition Therapy for the Management of Overweight and Obesity in Adults Developed in Collaboration with the European Federation of the Associations of Dietitians. Obes Facts. 2023;16(1):11-28, https://doi.org/10.1159/000528083.

38. García-Galbis MR, Gallardo DI, Martínez-Espinosa RM, Soto-Méndez MJ. Personalized Diet in Obesity: A Quasi-Experimental Study on Fat Mass and Fat-Free Mass Changes. Healthcare (Basel). 2021;9(9):1101, <u>https://doi.org/10.3390/healthcare9091101</u>.

39. Flint A, Gregersen NT, Gluud LL, Møller BK, Raben A, Tetens I, et al. Associations between postprandial insulin and blood glucose responses, appetite sensations and energy intake in normal weight and overweight individuals: a meta-analysis of test meal studies. Br J Nutr. 2007;98(1):17-25, <u>https://doi.org/10.1017/S000711450768297X</u>.